Polyphyllin I reverses the resistance of osimertinib in non-small cell lung cancer cell through regulation of PI3K/Akt signaling

被引：34

作者：

Lai, Lei ^{[1
]}

Shen, Qiuping ^{[1
]}

Wang, Yingjie ^{[1
]}

Chen, Liting ^{[2
]}

Lai, Jianjun ^{[2
]}

Wu, Zhibing ^{[2
]}

Jiang, Hao ^{[2
]}

机构：

[1] Tongxiang First Peoples Hosp, Dept Med Oncol, Tongxiang 314500, Zhejiang, Peoples R China

[2] Zhejiang Hosp, Dept Oncol, 12 Lingyin Rd, Hangzhou 310013, Zhejiang, Peoples R China

来源：

TOXICOLOGY AND APPLIED PHARMACOLOGY | 2021年 / 419卷

关键词：

Polyphyllin I; Osimertinib-resistance; Apoptosis; PI3K; Lung cancer; ACQUIRED-RESISTANCE; EGFR-TKI; GEFITINIB; COMBINATION; AZD9291; NSCLC; VII; MET;

D O I：

10.1016/j.taap.2021.115518

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Lung cancer is considered the main cause of cancer mortality worldwide. Osimertinib, a third-generation EGFRTKI, has been approved and administrated for treating patients with either EGFR T790M mutation or EGFR sensitive mutation. However, resistance to osimertinib emerges and has been considered to be the main obstacle in lung cancer treatment. Polyphyllin I is isolated from the natural herb Paris polyphylla and exhibits anti-cancer activities. In the present study, we identify Polyphyllin I to reverse the resistance of osimertinib in vitro and in vivo. The results showed that Polyphyllin I reversed the resistance of osimertinib through promoting apoptosis, modulating the PI3K/Akt signaling, and regulating the expression of apoptosis-related proteins in osimertinibresistant cell lines. In vivo study confirmed the results, showing that the tumor growth was significantly suppressed in the Polyphyllin I/osimertinib group compared to the osimertinib group. It has been clarified that Polyphyllin I could reverse the resistance of osimertinib in osimertinib-resistant non-small cell of lung cancer in vitro and in vivo. The underlying mechanism might be related to the downregulation of the PI3K/Akt signaling and increase of the expression of apoptosis-related proteins, suggesting that Polyphyllin I was a promising therapeutic agent for reversing the resistance of osimertinib.

引用

页数：8

共 37 条

[21] Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer [J].

Sato, Hiroki ;

Yamamoto, Hiromasa ;

Sakaguchi, Masakiyo ;

Shien, Kazuhiko ;

Tomida, Shuta ;

Shien, Tadahiko ;

Ikeda, Hirokuni ;

Hatono, Minami ;

Torigoe, Hidejiro ;

Namba, Kei ;

Yoshioka, Takahiro ;

Kurihara, Eisuke ;

Ogoshi, Yusuke ;

Takahashi, Yuta ;

Soh, Junichi ;

Toyooka, Shinichi .

CANCER SCIENCE, 2018, 109 (10) :3183-3196

[22]

Siegel RL., 2019, J Clin, V69, P7, DOI [DOI 10.3322/caac.20115, DOI 10.3322/CAAC.21772]

[23] AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells [J].

Taniguchi, Hirokazu ;

Yamada, Tadaaki ;

Wang, Rong ;

Tanimura, Keiko ;

Adachi, Yuta ;

Nishiyama, Akihiro ;

Tanimoto, Azusa ;

Takeuchi, Shinji ;

Araujo, Luiz H. ;

Boroni, Mariana ;

Yoshimura, Akihiro ;

Shiotsu, Shinsuke ;

Matsumoto, Isao ;

Watanabe, Satoshi ;

Kikuchi, Toshiaki ;

Miura, Satoru ;

Tanaka, Hiroshi ;

Kitazaki, Takeshi ;

Yamaguchi, Hiroyuki ;

Mukae, Hiroshi ;

Uchino, Junji ;

Uehara, Hisanori ;

Takayama, Koichi ;

Yano, Seiji .

NATURE COMMUNICATIONS, 2019, 10 (1)

[24] Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M [J].

Thress, Kenneth S. ;

Paweletz, Cloud P. ;

Felip, Enriqueta ;

Cho, Byoung Chul ;

Stetsonl, Daniel ;

Dougherty, Brian ;

Lai, Zhongwu ;

Markovets, Aleksandra ;

Vivancos, Ana ;

Kuang, Yanan ;

Ercan, Dalia ;

Matthews, Sarah E. ;

Cantarini, Mireille ;

Barrett, J. Carl ;

Jaenne, Pasi A. ;

Oxnard, Geoffrey R. .

NATURE MEDICINE, 2015, 21 (06) :560-562

[25] Combination therapy of gefitinib and miR-30a-5p may overcome acquired drug resistance through regulating the PI3K/AKT pathway in non-small cell lung cancer [J].

Wang, Fengfeng ;

Meng, Fei ;

Wong, Sze Chuen Cesar ;

Cho, William C. S. ;

Yang, Sijun ;

Chan, Lawrence W. C. .

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2020, 14

[26] Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer [J].

Wang, Honggang ;

Fei, Zhenghua ;

Jiang, Hao .

JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 134 (03) :190-196

[27] Polyphyllin I activates AMPK to suppress the growth of non-small-cell lung cancer via induction of autophagy [J].

Wu, Yezi ;

Si, Yuan ;

Xiang, Yuchen ;

Zhou, Tong ;

Liu, Xuewen ;

Wu, Mingwei ;

Li, Wenjuan ;

Zhang, Te ;

Xiang, Ke ;

Zhang, Liang ;

Zhao, Huzi ;

Liu, Ying .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2020, 687

[28] The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens [J].

Wu, Yi-Ying ;

Wu, Hung-Chang ;

Wu, Jia-En ;

Huang, Kuo-Yen ;

Yang, Shuenn-Chen ;

Chen, Si-Xuan ;

Tsao, Chao-Jung ;

Hsu, Keng-Fu ;

Chen, Yuh-Ling ;

Hong, Tse-Ming .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)

[29] Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis [J].

Xing, P. ;

Mu, Y. ;

Hao, X. ;

Wang, Y. ;

Li, J. .

CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (10) :1424-1431

[30] Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer [J].

Yang, Qi ;

Chen, Wenyu ;

Xu, Yufeng ;

Lv, Xiaodong ;

Zhang, Ming ;

Jiang, Hao .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 2018, 356 :1-7

← 1 2 3 4 →